On December 3, 2024, CVS Health entered into an Underwriting Agreement with Barclays, Citigroup, and Goldman Sachs to issue $3 billion in Junior Subordinated Notes. The issuance includes $2.25 billion of 7.000% Series A Notes due 2055 and $750 million of 6.750% Series B Notes due 2054.The sale is expected to close on December 10, 2024, subject to customary conditions. Net proceeds, after underwriters' discounts and expenses, are estimated at approximately $2.96 billion. The Notes are offered under CVS Health's Registration Statement on Form S-3ASR.Forward-looking statements in the report highlight potential risks and uncertainties. CVS Health advises caution in relying on these statements, as actual results may differ materially due to various factors outlined in their SEC filings.

On December 3, 2024, CVS Health entered into an Underwriting Agreement with Barclays, Citigroup, and Goldman Sachs to issue $3 billion in Junior Subordinated Notes. The issuance includes $2.25 billion of 7.000% Series A Notes due 2055 and $750 million of 6.750% Series B Notes due 2054.The sale is expected to close on December 10, 2024, subject to customary conditions. Net proceeds, after underwriters' discounts and expenses, are estimated at approximately $2.96 billion. The Notes are offered under CVS Health's Registration Statement on Form S-3ASR.Forward-looking statements in the report highlight potential risks and uncertainties. CVS Health advises caution in relying on these statements, as actual results may differ materially due to various factors outlined in their SEC filings.